

תכלית דיאטיה פלסואיד אולוריאן ב-31% האוכל פגיעה קשה וריגת

7% מטופלים פליסואיד, לעומת 1% נפנץ, 7% יתקבב אנטקופין, 7% איפיל גרא, 7% קיטין פיר, ריכ אנז – תריצת גברודסיה רכינה גאנז מסלן חימ – קיטין אפסילוקטינ גיאלאט.

[http://doctorsonly.co.il/wp-content/uploads/2011/11/27082012\\_psychiatry\\_Position-Paper-treatment-for-anorexia-nervosa-life-threatening-condition.pdf](http://doctorsonly.co.il/wp-content/uploads/2011/11/27082012_psychiatry_Position-Paper-treatment-for-anorexia-nervosa-life-threatening-condition.pdf)

**טיפול רפואי לאייז פלוסואיד**

**Ritsner MS, Lisker A, Arbitman M, Grinshpoon A.** Factor structure in the Camberwell Assessment of Need-Patient Version: The correlations with dimensions of illness, personality and quality of life of schizophrenia patients. *Psychiatry Clin Neurosci.* 2012 Oct;66(6):499-507.

<http://www.ncbi.nlm.nih.gov/pubmed/23066767>

**Peled A.** Personality disorders disturbances of the physical brain. *Med Hypotheses.* 2012 Jul 23.

<http://www.ncbi.nlm.nih.gov/pubmed/22832212>

**Silver H, Goodman C, Bilker WB.** Impairment in associative memory in healthy aging is distinct from that in other types of episodic memory. *Psychiatry Res.* 2012 May 15;197(1-2):135-9.

<http://www.ncbi.nlm.nih.gov/pubmed/22429482>

**Peled A.** Neuroanalysis: a method for brain-related neuroscientific diagnosis of mental disorders. *Med Hypotheses.* 2012 May;78(5):636-40. <http://www.ncbi.nlm.nih.gov/pubmed/22342251>

Bleich A, Baruch Y, **Hirschmann S**, Lubin G, Melamed Y, Zemishlany Z, Kaplan Z. Management of the suicidal patient in the era of defensive medicine: focus on suicide risk assessment and boundaries of responsibility. *Isr Med Assoc J.* 2011 Nov;13(11):653-6. <http://www.ncbi.nlm.nih.gov/pubmed/22279696>

**Grinshpoon A, Khawaled R, Polakiewicz J, Appelbaum PS, Ponizovsky AM.** Psychiatric hospitalization by court observation order in Israel: a ten year follow up study. *Isr J Psychiatry Relat Sci.* 2011;48(3):201-206.

<http://www.ncbi.nlm.nih.gov/pubmed/22141145>

**Ritsner MS, Arbitman M, Lisker A.** Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder. *J Nerv Ment Dis.* 2011 Nov;199(11):845-53.

<http://www.ncbi.nlm.nih.gov/pubmed/22048136>

Cloninger CR, Zohar AH, **Hirschmann S**, Dahan D. The psychological costs and benefits of being highly persistent: personality profiles distinguish mood disorders from anxiety disorders. *J Affect Disord.* 2012 Feb;136(3):758-66. <http://www.ncbi.nlm.nih.gov/pubmed/22036800>

Danovich L, Weinreb O, Youdim MB, **Silver H.** Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. *Psychopharmacology (Berl).* 2012 Apr;220(4):763-70. <http://www.ncbi.nlm.nih.gov/pubmed/21989809>

**Ritsner MS, Arbitman M, Lisker A, Ponizovsky AM.** Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Qual Life Res. 2012 Aug;21(6):1075-84. <http://www.ncbi.nlm.nih.gov/pubmed/21964946>

**Ritsner MS, Lisker A, Arbitman M.** Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. Qual Life Res. 2012 Jun;21(5):837-47. <http://www.ncbi.nlm.nih.gov/pubmed/21912845>

**Grinshpoon A, Barchana M, Lipshitz I, Rosca P, Weizman A, Ponizovsky AM.** Methadone maintenance and cancer risk: an Israeli case registry study. Drug Alcohol Depend. 2011 Dec 1;119(1-2):88-92. <http://www.ncbi.nlm.nih.gov/pubmed/21704463>

**Ritsner MS.** The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience. 2011 Sep 15;191:91-100. <http://www.ncbi.nlm.nih.gov/pubmed/21549182>

**Peled A.** Optogenetic neuronal control in schizophrenia. Med Hypotheses. 2011 Jun;76(6):914-21. <http://www.ncbi.nlm.nih.gov/pubmed/21482453>

**Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V.** L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011 Jan;72(1):34-42. <http://www.ncbi.nlm.nih.gov/pubmed/21208586>

**Silver H, Susser E, Danovich L, Bilker W, Youdim M, Goldin V, Weinreb O.** SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol. 2011 Jun;14(5):573-84. <http://www.ncbi.nlm.nih.gov/pubmed/21208484>

**Grinshpoon A, Lerner Y, Lurie TH, Zilber N, Sc D, M Ponizovsky A.** Post-discharge Contact with Mental Health Clinics and Psychiatric Readmission: A 6-month Follow-up Study. Isr J Psychiatry Relat Sci. 2011;48(4):262-267. <http://www.ncbi.nlm.nih.gov/pubmed/22572089>